After Treatment Ends: What Every Breast Cancer Survivor Needs to Know
Completing breast cancer treatment is a milestone worth celebrating. It is also, for many women, the moment when a new set of questions begins. What happens now? What does "staying healthy" actually look like? And how do you know whether the fatigue, joint aches or brain fog you are experiencing are normal or if they are something worth addressing?
Survivorship care is the phase of cancer care that begins at diagnosis and continues for the rest of your life. It shifts focus from treating cancer to supporting the whole person: managing long-term effects of treatment, reducing the risk of recurrence and actively optimizing health. For women with breast cancer, that work is both meaningful and evidence-backed.
Aromatase Inhibitors: An Important Tool With Real Side Effects
Many women with hormone receptor-positive breast cancer are prescribed aromatase inhibitors (AIs), which is the class of medications that include drugs like anastrozole, letrozole or exemestane. These drugs are often prescribed for five to ten years following treatment. AIs reduce estrogen to very low levels and significantly decrease the risk of recurrence. For some, they can be an effective tool in the oncology toolbox.
They also come with a meaningful side effect profile that deserves attention, not alarm.
Bone health is a central concern. Estrogen plays a central role in maintaining bone density, and when it is suppressed by AI therapy, bone loss accelerates. In the IBIS-II Bone Substudy, postmenopausal women with normal baseline bone density who received anastrozole lost approximately 4% of bone mineral density at both the lumbar spine and total hip over three years, compared with about 1–2% loss in women receiving placebo. For women who already have osteopenia at the start of AI therapy, this accelerated bone loss can increase the likelihood of progressing to osteoporosis if not proactively monitored and managed.
This is not a reason to avoid AIs; the recurrence-reducing benefit can be substantial for some individuals. It is, however, a reason to monitor bone density regularly, ensure adequate calcium and vitamin D intake, prioritize resistance and weight-bearing exercise, and in some cases discuss bone-protective medications with your oncologist.
It is also worth noting here that follow-up from the IBIS-II bone substudy showed that bone loss was at least partially reversible after anastrozole was discontinued.
Joint and muscle pain is sometimes called AI-associated arthralgia and affects a significant portion of women on these medications. This side-effect is one of the most common reasons women consider stopping therapy early. Studies suggest that up to one-third of women discontinue AI therapy before completing the full course, often because of musculoskeletal symptoms. Exercise, anti-inflammatory dietary and supplement support and, in some cases, switching between AI agents can all make a difference.
Cognitive changes are another consideration. Estrogen has neuroprotective properties, and suppressing it raises legitimate questions about cognitive function over time. The evidence here is mixed: some studies show no significant decline with aromatase inhibitor (AI) use alone, while others suggest subtle effects on memory, attention, and processing speed, particularly when AI therapy follows chemotherapy. That said, concerns about "brain fog" and cognitive performance are common in the clinical setting and should not be dismissed simply because the research is not definitive.
What this means practically is that cognitive symptoms during survivorship are worth naming, tracking and addressing. Contributing factors such as sleep disruption, fatigue, anxiety, depression, pain and other treatment effects should be evaluated, as they can significantly influence cognitive function. Supportive therapies can also play an important role. Exercise is one area where the evidence is particularly encouraging, with studies suggesting benefits for cognition, fatigue, mood, and overall quality of life. Cognitive rehabilitation strategies, mindfulness-based interventions, and attention to sleep health may also help patients maintain function and quality of life during long-term treatment.
Sexual health and genitourinary symptoms — vaginal dryness, discomfort with intercourse, decreased libido — are common with AI therapy and among the least-discussed side effects. They are real, they affect quality of life, and they are treatable. Non-hormonal vaginal moisturizers, local hormone replacement, pelvic floor physical therapy and open conversations with your provider are all appropriate starting points.
Cardiovascular Disease and Metabolic Health: The Bigger Picture
Here is something that surprises many breast cancer survivors: for women with early-stage breast cancer, cardiovascular disease is ultimately a greater cause of death than cancer recurrence. Some estimates suggest cardiovascular mortality accounts for roughly 35% of deaths in breast cancer survivors. This is not a reason for alarm, instead it a reason to pay attention to heart and metabolic health as seriously as you pay attention to your cancer surveillance.
Several factors converge to raise cardiovascular risk in breast cancer survivors. Treatment itself can be cardiotoxic. Certain chemotherapy regimens, radiation fields near the heart, and AI therapy (which removes cardioprotective estrogen) all contribute. On top of this, the treatment period itself often involves reduced physical activity, weight changes and metabolic disruption that persist well after therapy ends.
Metabolic syndrome refers to the cluster of elevated blood sugar, high blood pressure, abnormal lipids and excess abdominal fat. This area deserves particular focus because we see a significant impact on survivorship outcomes. A 2025 systematic review and meta-analysis found that breast cancer survivors with metabolic syndrome were 69% more likely to experience a cancer recurrence and 83% more likely to die from breast cancer than survivors without it. The presence of insulin resistance and chronic low-grade inflammation appears to create a biological environment that is less hostile to residual cancer cells. The metabolic picture matters for recurrence, not just for heart disease.
This means that keeping blood sugar stable, managing weight, addressing lipid profiles and reducing inflammation are not just general wellness goals, they are also cancer-relevant goals.
What the Evidence Says About Diet
Dietary patterns have a meaningful and increasingly well-documented role in breast cancer survivorship outcomes.
The Mediterranean diet is the most studied pattern in this context. A 2023 systematic review and meta-analysis found that higher adherence to the Mediterranean diet was associated with a 22% reduction in all-cause mortality among breast cancer survivors, along with a 33% reduction in non-breast cancer mortality. The 2024 DIANA-5 randomized controlled trial, which tested a Mediterranean-influenced dietary pattern in women at high risk of recurrence, provided direct evidence that dietary change can shift metabolic markers in breast cancer survivors in a favorable direction.
What makes this dietary pattern relevant is not a single food or nutrient, rather it is the overall effect on insulin sensitivity, inflammation and metabolic health. A Mediterranean-style approach emphasizes:
Abundant vegetables, legumes and whole grains as the foundation
Healthy fats from olive oil, nuts and fatty fish
Moderate intake of lean protein
Limited refined carbohydrates, sugar and ultra-processed foods
This pattern addresses multiple recurrence risk factors simultaneously: it supports metabolic health, reduces chronic inflammation, maintains a healthy weight and provides a rich array of antioxidants and phytonutrients.
Blood sugar management warrants particular attention. Research has shown that even fasting glucose levels that are within the normal range but trending higher are associated with increased recurrence risk. Insulin resistance and hyperinsulinemia appear to promote cancer cell proliferation, particularly in estrogen receptor-positive disease. Prioritizing low-glycemic foods, reducing refined carbohydrates and timing meals consistently are practical, actionable strategies.
Soy is worth a specific mention because it remains a source of confusion. A meta-analysis of five studies found that soy food intake, meaning whole soy foods like tofu, edamame and miso, was associated with reduced mortality in both ER-positive and ER-negative breast cancer survivors, in both pre and postmenopausal women. The concern about soy and estrogen-sensitive cancers largely stems from older data on isoflavone supplements and heavily processed forms of soy and has not been borne out in food-based research.
What the Evidence Says About Exercise
Exercise may be one of the most powerful survivorship interventions available, and it is still dramatically underutilized.
A comprehensive meta-analysis published in 2025 found that breast cancer survivors who met standard aerobic exercise guidelines of roughly 2.5 hours of moderate activity per week experienced approximately a 50% reduction in all-cause mortality compared to those who were minimally active. Additional reductions in risk were observed with up to about 4.5 hours of moderate activity per week.
Long-term data from the OptiTrain trial, presented at the 2024 European Society for Medical Oncology congress, found that a supervised exercise program combining resistance training and high-intensity aerobic work significantly reduced the risk of death at eight years of follow-up compared to usual care.
Exercise improves survival outcomes through multiple mechanisms. It reduces circulating estrogen and insulin levels, decreases chronic inflammation, improves body composition and cardiovascular fitness, and may directly inhibit tumor hypoxia, which is the low-oxygen microenvironment in which cancer cells can thrive.
For women on AI therapy, exercise is particularly important. Resistance and weight-bearing exercise are among the most effective interventions for preventing AI-associated bone loss, building and maintaining muscle and reducing the severity of joint symptoms. A 16-week combined aerobic and resistance exercise intervention was shown to significantly reduce cardiovascular risk scores in breast cancer survivors, while usual care led to increased risk over the same period.
A practical starting point:
Aim for at least 150 minutes of moderate aerobic activity per week. Think brisk walking, cycling, swimming, dancing
Include resistance or strength training at least twice a week, targeting all major muscle groups
If joint pain from AI therapy limits certain movements, working with a physical therapist or exercise specialist can be helpful to find sustainable alternatives
The goal is consistency over intensity, and any movement is better than none.
Other Areas That Deserve Attention
Survivorship care extends beyond diet and exercise. A comprehensive approach also addresses:
Sleep and stress. Poor sleep elevates cortisol, disrupts insulin regulation and promotes inflammation, which are all relevant to both recurrence risk and cardiovascular health. Fear of recurrence, anxiety and depression are common in breast cancer survivors and are associated in some studies with worse outcomes. A 2020 meta-analysis involving more than 280,000 breast cancer patients found that depression was associated with a 24% higher risk of recurrence, a 30% increase in all-cause mortality and a 29% increase in breast cancer-specific mortality. Anxiety was linked to a 17% higher recurrence risk, while the combination of anxiety and depression was associated with a 45% increase in cancer-specific mortality.
These findings do not mean that anxiety or depression directly cause cancer recurrence. What they do suggest is that our mental and physical health are deeply interconnected. The stress of a cancer diagnosis can affect sleep, energy, motivation, immune health and overall well-being, creating ripple effects that extend far beyond mood alone. Addressing sleep disturbances, anxiety, and depression is therefore not ancillary to cancer care—it is an important component of comprehensive survivorship care.
Lymphedema monitoring. For women who had lymph node surgery or radiation, lymphedema risk persists indefinitely. Early identification matters. Baseline arm measurements and follow-up monitoring every few months in the first years post-treatment can catch changes before they become established and harder to reverse.
Bone density surveillance. Regular DEXA scans are recommended for women on AI therapy, particularly those with preexisting bone loss. The combination of age-related bone loss and AI-induced bone loss can be significant, and proactive management changes outcomes.
Secondary cancer screening. Standard age-appropriate cancer screening (colonoscopy, lung cancer screening if indicated, skin checks) continues to apply and should not be overlooked in the focus on breast cancer follow-up.
Working Together Toward Your Healthiest Survivorship
The survivorship phase is an opportunity, not just a waiting period. There is meaningful evidence that the choices made after treatment, including what you eat, how you move, how well you sleep, how carefully you monitor and manage the side effects of ongoing therapy, all influence long-term outcomes.
Integrative oncology brings a lens to this phase that conventional follow-up care often does not have time for. It means looking at your full picture: the treatment you received, the medications you are on, your metabolic and cardiovascular health, your symptoms and quality of life and the specific, personalized interventions most likely to matter for you.
If you are navigating survivorship and wondering what your next steps should look like, I welcome the opportunity to work through that with you. A survivorship consultation can help clarify which monitoring is most important for your situation, develop a practical plan for diet, exercise and lifestyle, address ongoing side effects from treatment, and coordinate with your oncology team.
You have done the hard work of getting through treatment. Survivorship is where we build on it.
